van Helden, Erik J <br/><br/>
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.  [electronic resource] 

 -  Molecular oncology  11 2019 
 - 2361-2374 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1878-0261 
<br/><br/><label>Standard No.: </label>10.1002/1878-0261.12550  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Cetuximab--therapeutic use<br/>Circulating Tumor DNA--blood<br/>Colorectal Neoplasms--blood<br/>DNA Mutational Analysis<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Neoplasm Staging<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Treatment Outcome<br/>ras Proteins--genetics